Drug intelligence / Profile preview

Corenza C

Development stage
Unknown
Lead developer
ADOCK Ingram
Modality
Small Molecules
Administration
Oral
01

Overview

Corenza C is an over-the-counter combination medication developed and marketed by Adcock Ingram for the symptomatic relief of colds and influenza. It is formulated as an effervescent tablet containing paracetamol (650 mg), phenylephrine hydrochloride (10 mg), and vitamin C (250 mg). Paracetamol provides analgesic and antipyretic effects by inhibiting prostaglandin synthesis, primarily within the central nervous system. Phenylephrine acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors, leading to vasoconstriction of the blood vessels in the nasal passages and reducing mucosal swelling. Vitamin C is included as a nutritional supplement to support the immune system during infection. The product is indicated for the treatment of mild to moderate pain, fever, and nasal sinus and Eustachian tube congestion associated with respiratory tract infections.

Brand names
Corenza CCorenza Para-C Effervescent
Other names
Corenza Para-C
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1A (α1A)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Corenza C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corenza C.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call